<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1914">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398290</url>
  </required_header>
  <id_info>
    <org_study_id>20200449</org_study_id>
    <nct_id>NCT04398290</nct_id>
  </id_info>
  <brief_title>iNOPulse for COVID-19</brief_title>
  <acronym>NO-COVER</acronym>
  <official_title>Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roger Alvarez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bellerophon Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in
      subjects with COVID-19 who are hospitalized and require supplemental oxygen.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IRB AND FDA REVIEWS DEFERRED
  </why_stopped>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>As assessed per treating physician's discretion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 6 hours</time_frame>
    <description>Incidence of hypoxemia and hypotension as assessed per treating physician's discretion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of methemoglobinemia</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Incidence of increase to &gt; 5% total methemoglobin as assessed by pulse oximetry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with progression of respiratory failure</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Worsening respiratory status as defined by any one of the following: Implementation of High Flow Nasal Cannula (HFNC), non-rebreather mask, non-invasive ventilation, intubation and mechanical ventilation or need for intubation (in the event the patient is not intubated due to do not intubate (DNI) or do not resuscitate (DNR) status).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until resolution of hypoxemia</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>The number of days until hypoxemia is resolved as per treating physician assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Incidence of death during hospitalization and after discharge up to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of days of hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID-19</condition>
  <condition>Hypoxemia</condition>
  <condition>Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>iNOpulse Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive iNO delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will receive nitrogen gas delivered continuously together with supplemental oxygen by nasal cannula during hospitalization for up to 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled nitric oxide (iNO)</intervention_name>
    <description>iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour</description>
    <arm_group_label>iNOpulse Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrogen gas</intervention_name>
    <description>250 mcg/kg ideal body weight (IBW)/hour</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen gas</intervention_name>
    <description>Supplemental oxygen administered via nasal cannula</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_label>iNOpulse Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or above

          2. Proven COVID-19 viral infection. Non-confirmed highly suspicious suspects may be
             enrolled.

          3. Presence of radiographic findings compatible with pneumonia/pneumonitis.

          4. Patients requiring at least 3 L/m oxygen via nasal canula to maintain O2 above 92%.

          5. Female subjects of childbearing potential must have a negative pre-treatment pregnancy
             test (serum or urine).

          6. Willing and able to comply with treatment schedule and study procedures.

        Exclusion Criteria:

          1. Patient with severe hypoxemia who are unable to maintain an oxygen saturation (SpO2) &gt;
             88% on a maximum supplemental oxygen of 6 L/m by nasal cannula and a non-rebreather
             facemask.

          2. Participating in any other clinical trial for COVID-19

          3. Pregnancy, or positive pregnancy test in a pre-dose examination.

          4. Open tracheostomy.

          5. Clinical contra-indication, as deemed by the PI or their designee.

          6. Use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase
             methemoglobin such as intravenous lidocaine, or topical benzocaine or dapsone at
             screening.

          7. Known history or clinical evidence of heart failure or left ventricular dysfunction
             (LVEF &lt; 45%).

          8. Significant hemoptysis

          9. Unable to provide informed consent (proxy consent is acceptable if available)

         10. Any of the following conditions at time of possible enrollment: Fulminant Liver
             Failure, Acute Coronary Syndrome , Renal Failure requiring dialysis, Bacteremia,
             Shock, Cardiac arrest, Cardiac arrhythmia requiring acute treatment, Delirium /
             Encephalopathy, Severe Disseminated Intravascular Coagulation, Gastrointestinal
             hemorrhage, Hypoglycemia, Pneumothorax, Rhabdomyolysis / Myositis, Seizures, or Acute
             Stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger A Alvarez, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Hospitals &amp; Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Roger Alvarez</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine Pulmonary Vascular Diseases</investigator_title>
  </responsible_party>
  <keyword>hypoxemia</keyword>
  <keyword>respiratory failure</keyword>
  <keyword>COVID-19</keyword>
  <keyword>inhaled nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

